Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research^[1][2].

Lucatumumab (0.001-10 μg/mL; 4 h; 37 ℃) inhibit B-cell chronic lymphocytic leukemia (B-CLL) growth by ADCC-mediated cell lysis, with the average maximal lysis of B-CLL cells of 49%^[1].
Lucatumumab (0.1-10 μg/mL; 3 d) inhibits CD40L-induced signaling and viability of B-CLL cells^[1].
Lucatumumab (10 μg/mL; 24 h) inhibits cytokine secretion by B-CLL cells^[1].

Liquid

903512-50-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.